Restart Life Sciences raises C$100K to fund US expansion of Holy Crap Foods
What's the deal? Restart Life Sciences Corp., a Canadian company trading on the CSE under the ticker HEAL, has closed a non-brokered private placement of 833,334 units at C$0.12 each, raising C$100,000 in gross proceeds. The funds will establish a revolving purchase order financing source for its wholly owned subsidiary, Holy Crap Foods Inc., as it prepares to enter the US market.
CEO Steve Loutskou subscribed for 50% of the offering — 416,666 units — signalling personal conviction in the company's growth strategy. Other corporate insiders have also been accumulating shares on the open market.
Why now? The financing is tied to Holy Crap Foods' planned launch in the US. By setting up a dedicated revolving fund for purchase orders, Restart Life is trying to ensure its teams have working capital ready as it scales into North America ahead of the summer season.
What could go wrong? The raise is tiny — C$100,000 is a modest war chest for a US market entry, even for a small consumer brand. The heavy insider participation, while a vote of confidence, also means the company couldn't attract much outside capital. Related-party transactions of this kind can raise governance questions, though the company says it qualifies for exemptions under Canadian securities rules because the units issued to insiders don't exceed 25% of its market capitalisation.
The signal: Micro-cap life sciences and consumer health companies continue to rely on creative, small-scale financing mechanisms — like dedicated PO revolving funds — to bridge the gap between ambition and resources. CEO-led rounds show skin in the game but also highlight the fundraising challenges facing sub-scale public companies trying to break into competitive US markets.
Read more: wallstreet-online.de
